Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nynex Therapeutics
Cleveland, Ohio, United Statesexplorium.ai ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nynex Therapeutics is developing first-in-class, orally bioavailable small molecule inhibitors of deubiquitinases. These enzymes are implicated in the stabilization of oncogenic proteins and transcription factors that drive tumorigenesis. The company’s lead program is a pre-investigational new drug (pre-IND) candidate shown to be effective in preclinical models of cancer[2]. No clinical results have been reported yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule (deubiquitinase inhibitors)Small molecule (anti-cancer drugs)
- Industry
- Biotech
02
Partnerships
University of Michigan (technology originator and research partner)BioMotiv (drug development accelerator/founder)
Beyond the preview
Go deeper on Nynex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nynex Therapeutics.